SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026)
SAB Biotherapeutics (SABS) posted Income from Continuing Operations of 46506680.0 for Q1 2026, down 219.16% on a QoQ basis from 14571524.0 in Q4 2025, and down 323.92% year-over-year from 20769623.9 in Q1 2025.
SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 46506680.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 323.92% year-over-year to 46506680.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84277739.0 (down 118.02% YoY) and the FY2025 annual result came in at 73590831.0, down 71.9% from the prior year.
- Income from Continuing Operations was 46506680.0 for Q1 2026 at SAB Biotherapeutics, down from 14571524.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 985863.0 in Q1 2022 and bottomed at 46506680.0 in Q1 2026.
- A 5-year average of 11109910.41 and a median of 7848966.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 845.93% — and 2024, when it surged 56.25%.
- SAB Biotherapeutics' Income from Continuing Operations stood at 7848966.0 in 2022, then plunged by 191.21% to 22856763.0 in 2023, then jumped by 56.25% to 10000466.0 in 2024, then tumbled by 45.71% to 14571524.0 in 2025, then plunged by 219.16% to 46506680.0 in 2026.
- Business Quant data shows SABS's Income from Continuing Operations at 46506680.0 in Q1 2026, 14571524.0 in Q4 2025, and 12752386.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -46.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.51 Mn |
| Dec 31, 2025 | -14.57 Mn |
| Sep 30, 2025 | -12.75 Mn |
| Jun 30, 2025 | -10.45 Mn |
| Mar 31, 2025 | -10.97 Mn |
| Dec 31, 2024 | -10.00 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |